Huntington's Disease Clinical Trial
Official title:
Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
NCT number | NCT03628235 |
Other study ID # | C-001117-1 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 21, 2020 |
Est. completion date | June 21, 2022 |
Verified date | September 2022 |
Source | CHDI Foundation, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregiver support, and long-term care, which lead to substantial burden of illness. Very little data are available on the direct or indirect costs for HD. The direct medical costs of HD in the US have been summarized from retrospective commercial and Medicaid claims data analysis. The indirect and out-of-pocket costs of HD in the US have not been quantified. This study will help to bridge these gaps. This study is a single-assessment, cross-sectional online survey administered to Huntington disease gene expansion carriers (HDGECs) and companions of HDGECs by HD stage to understand the indirect and out-of-pocket costs of Huntington's disease in the US.
Status | Completed |
Enrollment | 233 |
Est. completion date | June 21, 2022 |
Est. primary completion date | June 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria for HDGECs: - Identified as an active participant in Enroll-HD (participants who have completed their last on site Enroll-HD visit within approximately 15 months) - Able to provide online or written informed consent. A LAR for HDGEC can provide written consent, if applicable - Identified as a participant with clinically diagnosed HD and has a CAG length = 40 - Site PI has access to HDGEC's medical records for the purpose of completing the Resource Utilization Questionnaire - Able to speak and understand both verbal and written English - Has adult onset of disease (disease symptoms manifested at age 20 years or older) - Has access to a computer/tablet/smartphone (if compatible) and internet services Stage classification of HDGECs: 1. Early stage HDGEC: CAG length = 40; DCL = 4, TFC = 11 2. Middle stage HDGEC: CAG length = 40; DCL = 4, 7 = TFC = 10 3. Late stage HDGEC: CAG length = 40; DCL = 4, 0 = TFC = 6 Exclusion Criteria for HDGECs: HDGECs will be excluded from the study if they have significant cognitive or any other impairment sufficient to interfere with study associated tasks as judged by the Site PI or Site PI's designee (exceptions will be made if a companion/LAR completes the survey on their behalf). Inclusion criteria for companions: - Able to provide online or written informed consent - Identified as the primary provider (unpaid) of supportive care of an HDGEC (HDGEC must be an Enroll-HD participant and have a CAG length = 40 and have adult onset of disease (disease symptoms manifested at age 20 years or older)) - Able to speak and understand both verbal and written English - Aged 21 years or older at time of survey - Has access to a computer/tablet/smartphone (if compatible) and internet services and has the technical skills required to complete an online survey Exclusion Criteria for companions: Companions will be excluded from the study if they are identified as paid or salaried caregivers; however, the HDGECs for whom they care may still be included in the study. |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University | Columbus | Ohio |
United States | Rocky Mountain Movement Disorder, P.C. | Englewood | Colorado |
United States | University of Texas Health Science Center at Houston | Houston | Texas |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Columbia University Medical Center | New York | New York |
United States | St. Joseph's Hospital and Medical Center | Phoenix | Arizona |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Washington University | Saint Louis | Missouri |
United States | University of Washington | Seattle | Washington |
United States | University of South Florida | Tampa | Florida |
United States | Hereditary Neurological Disease Centre, Inc. | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
CHDI Foundation, Inc. | IQVIA Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantify the indirect costs associated with productivity loss for HDGECs and companions | Productivity loss is measured by annual lost wages and it is collected in the survey's employment questionnaires and WPAI | 12 months | |
Primary | Quantify out-of-pocket expenses for HDGECs and companions | The indirect costs associated with the total annual out-of-pocket expenses. | 12 months | |
Primary | Identify the indirect costs associated with informal care received for HDGECs | The total informal care time received during a typical week | 12 months | |
Primary | Quantify the indirect costs associated with non-work caregiving time for companions | The indirect costs associated with the annual opportunity costs of companion | 12 months | |
Secondary | Identify the reasons for HDGEC and companion's unemployment or underemployment | 12 months | ||
Secondary | The proportion of Dual Role Companions, differentiated by HD stage of the companion | 12 months | ||
Secondary | To understand traditional disease staging system based on total functional capacity (TFC) | For HDGECs and Companions: Understand how the traditional disease staging system, based on the TFC score, relates to a staging system based on resource utilization questionnaire and comorbid conditions developed in Divino et al. (2013) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04120493 -
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02956148 -
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
|
Early Phase 1 | |
Terminated |
NCT02494778 -
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02208934 -
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
|
Phase 1 | |
Completed |
NCT02197130 -
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT01806896 -
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
|
Phase 2 | |
Completed |
NCT01502046 -
Neuroprotection by Cannabinoids in Huntington's Disease
|
Phase 2 | |
Terminated |
NCT00712426 -
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
|
Phase 3 | |
Completed |
NCT00670709 -
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
|
||
Completed |
NCT00029874 -
Minocycline in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02231580 -
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
|
Phase 2 | |
Completed |
NCT02215616 -
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
|
Phase 2 | |
Not yet recruiting |
NCT02551705 -
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
|
N/A | |
Active, not recruiting |
NCT02101957 -
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
|
Phase 2/Phase 3 | |
Completed |
NCT01521832 -
Escalating Dose Study in Healthy Volunteers With SEN0014196
|
Phase 1 | |
Completed |
NCT00990613 -
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
|
Phase 1 | |
Completed |
NCT00975481 -
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
|
Phase 1 | |
Completed |
NCT00387270 -
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00095355 -
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease
|
Phase 2 |